ArticleJournal of immunology research2026
Mesenchymal Stem Cells Ameliorate Acute-on-Chronic Liver Failure Associated With Expansion of Immunoregulatory Hepatic NKp46
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND AND
aimsHepatitis B virus (HBV)-related acute-on-chronic liver failure (HBV-ACLF) is a life-threatening syndrome characterized by rapid hepatic decompensation and immune dysregulation, with limited treatment options. Mesenchymal stem cells (MSCs) have shown therapeutic potential, but their precise mechanisms-particularly regarding their interaction with hepatic NKp46
methodsPeripheral NK cells were analyzed in ACLF patients receiving MSC infusion or standard therapy. Flow cytometry assessed NK frequency, phenotype, and correlations with survival. Murine ACLF was induced by carbon tetrachloride (CCL
resultsFrequency of peripheral blood NK cells from ACLF patients was upregulated after MSCs infusion, which correlated with liver function recovery. Phenotypic changes included upregulation of NKG2A and downregulation of NKp30 and FasL. MSC infusion effectively rescued ACLF mice and increased NK cell frequency in both blood and liver. Strikingly, NKp46
conclusionsMSC infusion holds significant clinical promise for ACLF patients. In addition to promoting liver regeneration, the immunomodulatory effect of MSCs on hepatic NKp46
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.